You are here

  • Home
  • Archive
  • Volume 95, Issue 10
  • Modelling the prevalence of age-related macular degeneration (2010–2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy

Article info

Article menu
Download PDFPDF
Clinical science
Original article
Modelling the prevalence of age-related macular degeneration (2010–2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy

Authors

  1. Correspondence to Dr Darwin C Minassian, Institute of Ophthalmology, UCL, Bath Street, London EC1V 9EL, UK; d.minassian{at}ucl.ac.uk
View Full Text

Citation

Minassian DC, Reidy A, Lightstone A, et al
Modelling the prevalence of age-related macular degeneration (2010–2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy
British Journal of Ophthalmology 2011;95:1433-1436.

Publication history

  • Accepted December 26, 2010
  • First published February 12, 2011.
Online issue publication 
March 22, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.